Antibacterial 01
Resistant bacteria
A patented composition is structurally disruptive in a way pathogens cannot route around. No evolutionary resistance has been observed across two decades of independent study.
Pre-clinical Pharmaceutical Platform Est. 2023 · Monterey, CA
An Integrated Pharmaceutical Antibacterial & Antiviral Platform
Stage: Pre-clinical
Advancing proprietary, dual-action mechanisms engineered to neutralize viral transmission and overcome antimicrobial resistance at the molecular source.
20+ yrs
No observed evolutionary resistance across independent study
2
Parallel patented assets — botanical and synthetic
3
Expedited FDA pathways in play
WHO list
Multi-drug-resistant target pathogens
The opportunity
A global threat that conventional antibiotics are structurally unequipped to meet.
The World Health Organization ranks antimicrobial resistance among the leading global public health threats. Conventional antibiotics act on a single target site; pathogens inevitably select for resistance, and the pipeline of new mechanisms has stalled.
Logix approaches the problem at the molecular source. A single patented engine is structurally disruptive rather than site-specific, removing the single point of failure that resistance exploits, and extending the same mechanism to viral transmission and tissue repair.
The platform · LBX242
One patented engine.
Three therapeutic fronts.
LBX242 is a patented composition, treated as a proprietary engine rather than disclosed as a formula. Not a pipeline of unrelated molecules: one structurally disruptive composition, expressed across three modes of action.
Antiviral 02
Viral transmission
The same composition acts against enveloped respiratory viruses at the point of entry, neutralizing transmission before infection takes hold.
Angiogenic 03
Tissue repair
Beyond defense, the composition promotes angiogenesis and supports a regenerative tissue-repair pathway, addressing the conditions required for healing.
Regulatory momentum
Two assets.
Two FDA pathways.
Two independently patented compositions — one botanical, one synthetic — multiply delivery options and de-risk capital across parallel pathways. Both express the same patented LBX242 composition.
Asset 01
Botanical matrixLBX242
- Composition
- A patented botanical matrix.
- Human use
- Three decades of broad global human use of the natural composition from which LBX242 is derived.
- FDA pathway
- 505(b)(1) botanical pathway, qualifying on prior human use.
Asset 02
Synthetic small moleculeLBX242
- Composition
- Synthetic LBX242 derivative, engineered for precision delivery.
- Designation
- QIDP under the GAIN Act — five additional years of exclusivity and Fast Track.
- FDA pathway
- LPAD pathway, scaling trial burden to a resistant population.
505(b)(1) / 505(b)(2)
Dual new-drug application routes
LPAD / GAIN Act
Limited-population and antimicrobial incentives
QIDP
Qualified Infectious Disease Product
Fast Track
Expedited FDA review
Institutional validation
Strategic agreement with Mayo Clinic.
Mayo Clinic
Partner
Independent Medical Advisory Board
Leadership
The people behind the platform.
Gavin Gear
Founder & Chief Executive Officer
Mark Morris
Co-Founder & Chief Financial Officer
Dr. Marc Stevens
Orthopedic Surgeon, Chief Medical Officer
Brett Edmonds
Co-Founder, Board Member
Gateway
Scientific, regulatory, and partnership inquiries.
Access to the clinical data deck, the executive summary, and mechanism-of-action briefings is provided to qualified parties under confidentiality.
- Phone
- +1 (800) 916-1220
- Office
- Monterey, California, United States